Get started
Author

John George Knecht

Observed names: J.G. Knecht, John G. Knecht
OpenAlex ID: A5042157142
Vilastobart (XTX101), a tumor-activated, Fc-enhanced anti–CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with MSS CRC.
2025 · Marwan Fakih, Nicholas C. DeVito, et al. · Journal of Clinical Oncology · 7
PDF
A first-in-human study of XTX301, a masked, tumor-activated interleukin-12 (IL-12), in patients with advanced solid tumors.
2023 · John George Knecht, Anurag Gupta, et al. · Journal of Clinical Oncology · 3
PDF
A randomized phase 2 non-inferiority trial of (Z)-endoxifen and exemestane + goserelin as neoadjuvant treatment for premenopausal women with ER+/HER2- breast cancer (EVANGELINE).
2023 · Matthew P. Goetz, Vera Jean Suman, et al. · Journal of Clinical Oncology · 3
Bria-IMT + checkpoint inhibitor: Phase I/II survival results compared to benchmark trials in metastatic breast cancer.
2025 · Saranya Chumsri, Chaitali Singh Nangia, et al. · Journal of Clinical Oncology · 1
Phase 1/2 study of XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with advanced solid tumors and in MSS CRC.
2025 · Joel R Hecht, Diwakar Davar, et al. · Journal of Clinical Oncology · 1
Outcomes of advanced/metastatic breast cancer (aMBC) treated with BRIA-IMT, an allogeneic whole cell immunotherapy.
2024 · Carmen Julia Calfa, Chaitali Singh Nangia, et al. · Journal of Clinical Oncology · 1
PDF
Abstract PS3-04: Overall Survival Results of Bria-IMT Allogenic Whole Cell-Based Cancer Vaccine
2025 · Saranya Chumsri, Chaitali Nangia, et al. · Clinical Cancer Research
Impact of HLA matching on clinical outcomes in a phase 2 trial of Bria-IMT plus anti PD1 in advanced breast cancer.
2025 · Carmen Calfa, Chaitali Singh Nangia, et al. · Journal of Clinical Oncology
133P Phase I/II study of XTX101: A masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors
2023 · D. Davar, J.G. Knecht, et al. · Immuno-Oncology Technology
PDF
Phase 1/2 study of XTX101, a masked, tumor-selective Fc-modified anti-CTLA4, in patients with advanced solid tumors.
2023 · Diwakar Davar, John George Knecht, et al. · Journal of Clinical Oncology
PDF
Abstract CT143: Whole cell antigen presenting immune stimulating cells (Bria-IMT) for the treatment of metastatic breast cancer
2023 · Saranya Chumsri, Minal Barve, et al. · Cancer Research
Works count: 11
Citation count: 16
H-index: 3
I10-index:
Year
Topic
Type